Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
DiaceuticsDIUXF 80 3-1 Month Momentum % is 19.76% as of Jul. 16, 2026. GuruFocus rates DIUXF with a GF Score™ of 80/100 and a GF Value™ of $2.05 (Fairly Valued). The stock has 1 warning sign investors should review. Among 679 Healthcare Providers & Services companies, Diaceutics ranks worse than 73.34% on this metric.
3-1 Month Momentum % is the total return of the stock from 3-month ago to 1-month ago. As of today (2026-07-16), Diaceutics's 3-1 Month Momentum % is 19.76%.
The industry rank for Diaceutics's 3-1 Month Momentum % or its related term are showing as below:
DIUXF's 3-1 Month Momentum % is ranked worse than 73.34% of 679
companies
in the Healthcare Providers & Services industry
Industry Median: -3.96
vs DIUXF: 19.76
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 3-1 Month Momentum % measures the total return to a stock over the past three months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
Diaceutics 3-1 Month Momentum % Related Terms
DIUXF vs VEEV, BTSG, TEM: 3-1 Month Momentum % Comparison
For the Health Information Services subindustry, Diaceutics's 3-1 Month Momentum %, along with its competitors' market caps and 3-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Diaceutics 3-1 Month Momentum % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Diaceutics's 3-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where Diaceutics's 3-1 Month Momentum % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Diaceutics (DIUXF) has a 3-1 Month Momentum % of 19.76% as of Jul. 16, 2026. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Diaceutics and its competitors. According to the industry distribution chart, Diaceutics ranks #498 out of 679 companies in the Healthcare Providers & Services industry, placing it in the top 73.3%.
Is Diaceutics' 3-1 Month Momentum % too high?
Diaceutics' current 3-1 Month Momentum % is 19.76%. Based on the distribution chart, Diaceutics ranks #498 out of 679 companies in the Healthcare Providers & Services industry, which is below the industry midpoint. Overall, Diaceutics has a GF Score™ of 80/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Diaceutics' 3-1 Month Momentum % compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, Diaceutics ranks #498 out of 679 companies for 3-1 Month Momentum %. This places Diaceutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-1 Month Momentum % for a Healthcare Providers & Services company?
A good 3-1 Month Momentum % depends on the Healthcare Providers & Services industry context. However, 3-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-1 Month Momentum % mean?
A high 3-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Diaceutics and its competitors. Diaceutics's current 3-1 Month Momentum % is 19.76%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Diaceutics stock overvalued right now?
Based on GuruFocus' analysis, Diaceutics (DIUXF) is currently considered Fairly Valued. The stock's GF Value™ is $2.05, compared to a current price of $2.00 — trading 2.4% below its estimated fair value. The current 3-1 Month Momentum % is 19.76%. Diaceutics' overall GF Score™ is 80/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-1 Month Momentum % calculated?
3-1 Month Momentum % is calculated from a company's financial statements. For Diaceutics (DIUXF), the current 3-1 Month Momentum % is 19.76% as of Jul. 16, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Diaceutics (DIUXF) Overvalued in 2026?
Based on GuruFocus' analysis, Diaceutics stock appears to be undervalued.
The current stock price of $2.00 is trading 2.4% below its estimated GF Value™ of $2.05.
GuruFocus considers Diaceutics to be Fairly Valued.
Key valuation signals for DIUXF:
3-1 Month Momentum %: 19.76%
GF Value™: $2.05 vs. price of $2.00 (2.4% below fair value)
No single metric tells the full story. See the DIUXF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Diaceutics PLC is a data analytics and implementation services company that services the pharmaceutical industry. It provides integrated commercialization solutions that help biopharma companies maximize patient access, accelerate uptake, and improve the lifetime value of their therapies. The group's services span the full commercial lifecycle, from pre-launch ideas through to mature brand optimization, delivered through an integrated combination of data, technology, and expertise. Its DXRX Data Solutions include DXRX Signal, DXRX Physician Segmentation, DXRX Lab Segmentation, and DXRX Disease Testing Rate Tracker. Geographical market by customer location in the UK, North America, Europe, Asia, and the rest of the world.
80GF Score
Get the complete analysis for DIUXF
3-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DIUXF has been successfully added to your 
